In NSCLC, some specific targets that have already been studied are oncogenes, such as EGFR, KRAS, or ALK, and immune checkpoints, such as PD-1/PD-L1 and CTLA-4. This evidence concerns the gene CD274 and non-small cell lung carcinoma.